OSE Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of no…
Biotechnology
FR, Nantes [HQ]
OSE.PA/Financial Reporting
Income Statements
12 Sheets · Starting from 2012In Million EUR. Margins, Growth Rates In %
| Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | 6.00 | 24.00 | 25.00 | 10.00 | 26.00 | 18.00 | 2.00 | |
|
EPS
|
-0.18 | -0.03 | -0.36 | -0.59 | 1.65 | -0.73 | 0.35 | -0.31 | -1.06 | -0.93 | -0.96 | -1.18 | |
| Diluted in mil. | -0.18 | -0.03 | -0.36 | -0.59 | 1.52 | -0.73 | 0.35 | -0.31 | -1.06 | -0.93 | -0.96 | -1.18 | |
|
Profit
|
- - | - - | - - | - - | - - | 6.00 | 24.00 | 25.00 | 10.00 | 26.00 | 18.00 | 2.00 | |
| Gross Margin | - - | - - | - - | -225.00 | 95.82 | 100.00 | 99.98 | 99.97 | 100.01 | 100.00 | 100.00 | 100.00 | |
| Pre Tax | -1.00 | - - | -2.00 | -5.00 | 17.00 | -12.00 | 4.00 | -4.00 | -24.00 | -21.00 | -23.00 | -29.00 | |
| Profit Margin | - - | - - | - - | -139,325.00 | 4,593.21 | -190.68 | 19.25 | -17.43 | -233.89 | -81.95 | -128.15 | -1,302.47 | |
| ETR | -121.50 | -100.00 | -0.07 | -0.20 | 17.47 | -17.57 | 16.63 | -2.85 | 32.06 | 21.84 | 24.28 | 20.70 | |
| Net | -1.00 | - - | -2.00 | -5.00 | 20.00 | -10.00 | 5.00 | -4.00 | -16.00 | -16.00 | -17.00 | -23.00 | |
| Profit Margin | - - | - - | - - | -139,600.00 | 5,395.82 | -157.18 | 22.45 | -17.93 | -158.91 | -64.05 | -97.04 | -1,032.91 | |
| EBITDA | -1.00 | - - | - - | -5.00 | - - | -12.00 | 4.00 | -4.00 | -24.00 | -19.00 | -20.00 | -28.00 | |
| EBITDA Margin | - - | - - | - - | -133,025.00 | -120.10 | -187.10 | 20.29 | -17.64 | -230.43 | -73.62 | -111.90 | -1,296.99 | |
| Operating Income | -1.00 | - - | -2.00 | -5.00 | - - | -12.00 | 4.00 | -5.00 | -24.00 | -21.00 | -24.00 | -32.00 | |
| Operating Margin | - - | - - | - - | -135,500.00 | -148.04 | -188.94 | 19.82 | -19.50 | -237.44 | -83.53 | -131.34 | -1,452.85 | |
| Interest Income | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Loss | -1.00 | - - | -2.00 | -5.00 | -17.00 | -19.00 | -19.00 | -31.00 | -35.00 | -48.00 | -42.00 | -34.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Operating Expenses
|
-1.00 | - - | -2.00 | -5.00 | -17.00 | -19.00 | -19.00 | -30.00 | -34.00 | -45.00 | -38.00 | -31.00 | |
| R&D | -1.00 | - - | -2.00 | -2.00 | -8.00 | -18.00 | -19.00 | -25.00 | -27.00 | -33.00 | -29.00 | -24.00 | |
| G&A | - - | - - | - - | -1.00 | -2.00 | -3.00 | -3.00 | -3.00 | -4.00 | -8.00 | -6.00 | -6.00 | |
| SG&A | - - | - - | - - | -3.00 | -3.00 | -4.00 | -4.00 | -5.00 | -6.00 | -11.00 | -8.00 | -6.00 | |
| S&M | - - | - - | - - | -1.00 | - - | -1.00 | - - | -1.00 | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | - - | -2.00 | -3.00 | -3.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -2.00 | |
| Other Expenses | - - | - - | - - | - - | -18.00 | - - | - - | - - | - - | - - | - - | -3.00 | |
|
WA Shares Outstanding
|
7.00 | 7.00 | 7.00 | 9.00 | 13.00 | 14.00 | 15.00 | 14.00 | 15.00 | 18.00 | 18.00 | 19.00 | |
| Diluted | 7.00 | 7.00 | 7.00 | 9.00 | 13.00 | 14.00 | 15.00 | 14.00 | 15.00 | 18.00 | 18.00 | 19.00 |